Project Grant R01DA065318
Award Date 9/1/26
Completion Date 4/30/31
Dollars Obligated $657K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
- The National Institute on Drug Abuse awarded Virginia Commonwealth University $1,182,810 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 15, 2026, to identify and characterize non-nicotine compounds in electronic nicotine delivery systems that drive abuse liability through functional activity at nicotinic acetylcholine receptor subtypes. The award funds high-throughput screening methods to comprehensively identify pharmacologically active non-nicotine constituents in...
- The National Institute on Drug Abuse awarded Virginia Commonwealth University $149,766 on August 17, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research on LYNX1 allosteric modulation of α3β4-nicotinic receptors and its relevance to nicotine use disorder. The fellowship project addresses two unresolved questions in nicotine addiction neurobiology. The recipient will conduct saturation and competition binding assays on heterologously expressed...
- The National Institute on Drug Abuse awarded Virginia Commonwealth University $177,216 on January 11, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on muscarinic receptor modulation as a pharmacological approach to stimulant use disorder. The project, titled "Muscarinic Receptor Mediation of Cocaine-Dependent Reward Signals: Impact of Pharmacological Modulation," investigates how M1 and M4 muscarinic acetylcholine receptor subtypes...
- The National Institute on Drug Abuse awarded Virginia Commonwealth University $684,736 under Project Grant R01DA063716 on August 15, 2026, to investigate mu opioid receptor trafficking and signaling at neuronal primary cilia. The research comprises three integrated aims. Aim 1 investigates mu opioid receptor trafficking at cilia, focusing on agonist-induced desensitization, internalization, and phosphorylation. Aim 2 defines the recycling pathway's role in ciliary targeting and uses proximity...
- The National Institute on Drug Abuse awarded the Research Foundation For Mental Hygiene, Inc. (operating through its New York State Psychiatric Institute division) $195,804 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a five-year research project examining how cannabis influences nicotine use among young and emerging adults (ages 18–35) who use electronic nicotine delivery systems. The study integrates human laboratory methods with...
- The National Institute on Drug Abuse awarded Duke University $722,472 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized, double-blinded study examining very low nicotine content cigarettes as a smoking cessation intervention for individuals with chronic back pain. The research addresses high comorbidity between tobacco smoking and chronic pain, where nicotine's mild anti-nociceptive effects create powerful negative reinforcement and...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $700,254 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to examine how combined nicotine and opioid exposure alters the prefrontal cortex in opioid use disorder. The research addresses the gap between current OUD treatments and patient outcomes, particularly the role of nicotine dependence as a confounding factor. Between 80–90 percent of individuals with OUD smoke, yet smoking...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $631,094 on August 1, 2026, for research evaluating the neurocognitive, psychomimetic, and abuse-related effects of emerging psychoactive cannabinoids under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a five-year project (August 1, 2026 through June 30, 2031) examining vaporized delta-8 tetrahydrocannabinol (D8-THC) and hexahydrocannabinol (HHC)—novel cannabinoids marketed as legal...
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $211,680 under NIDA's Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2026. The recipient will conduct mixed-methods research characterizing hemp-derived alternative cannabinoid product use in natural settings. The project comprises two national, decentralized studies: an online survey and a six-month naturalistic ecological momentary assessment study. Research will assess alternative...
- The National Institute on Drug Abuse awarded the University of California, Irvine $142,003 on October 9, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the interaction between nicotine and GPR3 (G-protein coupled receptor 3), focusing on gene expression, cell activity, and withdrawal mechanisms. The research examines whether nicotine exposure regulates GPR3 expression in brain regions related to nicotine intake and withdrawal, how GPR3 agonists alter...